Original Article

Inflammatory myopathies: One-center experience

Volume 1 · Issue 3 Publish Date: September 3, 2019
Full Text PDF
DOI
Metin Işık
Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
Şule Bilgen
Department of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey; Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
İsmail Doğan
Department of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Levent Kılıç
Department of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Işık, M., Bilgen, Şule, Doğan, İsmail, & Kılıç, L. (2019). Inflammatory myopathies: One-center experience. European Journal of Rheumatology, 1(3), 96–100. https://doi.org/10.5152/eurjrheumatol.2014.033
Full Text Full Text PDF

Abstract

Abstract

Objective: Our aim was to report our experience with inflammatory myositis.

 

Material and Methods: In total, 60 patients were evaluated retrospectively, and 43 of them (71.7%) were female. The median age was 45 (17-81). Of all patients, 33 (55%) were diagnosed as polymyositis, 22 (36.6%) as dermatomyositis (classical, amyopathic, and malignancy-associated), and 5 (8.33%) as undifferentiated myositis. The 3 patients with malignancy-associated dermatomyositis had lung cancer, nasopharyngeal carcinoma, and endometrial cancer. Two patients with polymyositis had a history of low-grade gastric mixed tumor and thymoma but were diagnosed 7 and 12 years ago, and no recurrences have been reported during the routine controls.

 

Results: All patients, other than two with malignancy-associated dermatomyositis, were treated via immunosuppressive agent, and the third patient with lung cancer was diagnosed later and gave up immunosuppressive therapy. Thirty-nine (65%) of the patients were treated via oral low-dose steroid, and 19 (31.7%) were treated via intravenous high-dose pulse steroid therapy. All patients were treated with steroid, which was tapered by time, and 23 (38.3%) were treated with azathioprine, 6 (10%) were treated with cyclophosphamide, 3 (5%) were treated with methotrexate, and 6 (10%) were treated with isolated steroid therapy at the time of diagnosis. The median follow-up period was 37 (2-135) months. Six patients (10%) have died-3 due to myocardial infarction, 1 due to septic shock, 1 due to malignancy, and 1 with an unknown reason. The 5-year survival rate was 76.9%, and the 10-year survival rate was 40%.

 

Conclusion: Other than the high ratio of PM in our series, all other results were compatible with the literature. We faced few resistant diseases; therefore, biologic agents were used rarely. 

 

Article Info
Published In
Journal European Journal of Rheumatology
Volume / Issue Volume 1 · Issue 3
Pages 96-100
History
Published Online September 3, 2019
Copyright
Affiliations
Metin Işık
Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
Şule Bilgen
Department of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey; Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
İsmail Doğan
Department of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Levent Kılıç
Department of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Cite this Article
Işık, M., Bilgen, Şule, Doğan, İsmail, & Kılıç, L. (2019). Inflammatory myopathies: One-center experience. European Journal of Rheumatology, 1(3), 96–100. https://doi.org/10.5152/eurjrheumatol.2014.033
Share
Outlines